Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine

Cancer Research

Volumn 60, Issue 14, 2000, Pages 3782-3789

  Dakappagari, Naveen K ^a   Douglas, Donna B ^b,d   Triozzi, Pierre L ^a,c   Stevens, Vernon C ^b,c   Kaumaya, Pravin T P ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CHIMERIC PROTEIN; EPITOPE; HYBRID PROTEIN; ONCOPROTEIN; PEPTIDE; VIRUS FUSION PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER IMMUNIZATION; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CHIMERA; COMPUTER ANALYSIS; CONTROLLED STUDY; IMMUNOGENICITY; MEASLES VIRUS; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE ANALYSIS; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; B-LYMPHOCYTES; CANCER VACCINES; CELL DIVISION; CELL LINE; DISULFIDES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MAMMARY NEOPLASMS, EXPERIMENTAL; MEASLES VIRUS; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PEPTIDES; POINT MUTATION; PROTEIN CONFORMATION; PROTEIN FOLDING; RABBITS; RATS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0034660850     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
2. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor
3. Bivalence of EGF-like ligands drives the ErbB signaling network
4. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: From orphanhood to multiple stromal ligands
5. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues
6. The role of the HER-2/neu oncogene in gynecologic cancers
7. The HER-2/neu oncogene: Prognostic factor, predictive factor and target for therapy
8. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
9. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
10. Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy
11. The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions
12. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand
13. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
14. Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification
15. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen
16. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo
17. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo
18. Prevention of breast tumour development in vivo by downregulation of the p185neu receptor
19. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
20. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
21. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
22. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth
23. Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2
24. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors
25. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells
26. ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies
27. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
28. Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2
29. Preclinical studies with Fc(γ)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu-overexpressing breast cancer
30. Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector
31. A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas
32. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice
33. Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer
34. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein
35. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
36. Prediction and identification of a T cell epitope in the fusion protein of measles virus immunodominant in mice and humans
37. Immunogenicity and antigenicity of a promiscuous T cell epitope and a topographic B cell determinant of the protein antigen LDH-C4
38. Promiscuous T cell epitopes of tetanus toxin, and measles virus enhances immune responses to B cell epitopes of the protein antigen LDH-C4
39. Relative immunogenicity and efficacy of two synthetic chimeric peptides of fimbrin as vaccinogens against nasopharyngeal colonization by nontypeable Haemophilus influenzae in the chinchilla
40. Peptides of 23 residues or greater are required to stimulate a high affinity class II-restricted T cell response
41. Peptide vaccines incorporating a "promiscuous" T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity
42. Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction
43. De novo engineering of protein immunogenic and antigenic determinants
44. Engineered topographic determinants with αβ, βαβ, and βαβα topologies show high affinity binding to native protein antigen LDH-C4
45. Phase I clinical trial of a World Health Organisation birth control vaccine
46. Synthetic peptide vaccines: Dream or reality
47. Regulation of N-linked core glycosylation: Use of a site-directed mutagenesis approach to identify Asn-Xaa-Ser/Thr sequons that are poor oligosaccharide acceptors
48. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease
49. Cellular recognition and HLA restriction of a midsequence HBsAg peptide in hepatitis B vaccinated individuals
50. Engineered topographic determinants with αβ, βαβ, and βαβα topologies show high affinity binding to native protein antigen (lactate dehydrogenase-C4)
51. Synthesis and biophysical characterization of engineered topographic immunogenic determinants with αα topology
52. Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185
53. Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185
54. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
55. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness
56. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: Implications for human breast cancer
57. Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation
58. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake
59. Recombinant epithelial cell mucin (MUC-1) expressed in baculovirus resembles antigenically tumor associated mucin, target for cancer immunotherapy
60. Glycosylation affects both the three-dimensional structure and antibody binding properties of the HIV-11IIB GP120 peptide RP135
61. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
62. Nonparametric estimation from incomplete observations
63. Evaluation of survival data and two new rank order statistics arising in its consideration